Protagonist Therapeutics (PTGX) Research & Development (2017 - 2025)
Historic Research & Development for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $40.0 million.
- Protagonist Therapeutics' Research & Development rose 1121.21% to $40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.8 million, marking a year-over-year increase of 1189.27%. This contributed to the annual value of $138.1 million for FY2024, which is 1495.24% up from last year.
- Protagonist Therapeutics' Research & Development amounted to $40.0 million in Q3 2025, which was up 1121.21% from $37.0 million recorded in Q2 2025.
- In the past 5 years, Protagonist Therapeutics' Research & Development registered a high of $40.0 million during Q3 2025, and its lowest value of $24.2 million during Q1 2021.
- For the 5-year period, Protagonist Therapeutics' Research & Development averaged around $32.8 million, with its median value being $33.7 million (2024).
- Per our database at Business Quant, Protagonist Therapeutics' Research & Development skyrocketed by 13104.72% in 2021 and then plummeted by 3126.42% in 2022.
- Over the past 5 years, Protagonist Therapeutics' Research & Development (Quarter) stood at $38.4 million in 2021, then decreased by 22.12% to $29.9 million in 2022, then fell by 3.3% to $28.9 million in 2023, then increased by 20.78% to $34.9 million in 2024, then increased by 14.61% to $40.0 million in 2025.
- Its Research & Development stands at $40.0 million for Q3 2025, versus $37.0 million for Q2 2025 and $35.9 million for Q1 2025.